Previous close | 0.2000 |
Open | 0.3300 |
Bid | 0.1500 |
Ask | 1.0500 |
Strike | 15.00 |
Expiry date | 2024-07-19 |
Day's range | 0.2000 - 0.3500 |
Contract range | N/A |
Volume | |
Open interest | 38 |
TAMPA, Fla. & LOS ANGELES, May 14, 2024--Moffitt Cancer Center, a world-renowned cancer treatment and research center, and Fulgent Pharma, a subsidiary of Fulgent Genetics, Inc. (NASDAQ: FLGT) and a leading nanobiotechnology company specializing in innovative cancer therapeutics, announced today a strategic partnership aimed at advancing cancer treatment through clinical development and pre-clinical co-development initiatives. This collaboration combines Moffitt’s cutting-edge clinical capabilit
Fulgent Genetics ( NASDAQ:FLGT ) First Quarter 2024 Results Key Financial Results Revenue: US$64.5m (down 2.5% from 1Q...
Fulgent Genetics, Inc. (NASDAQ:FLGT) Q1 2024 Earnings Call Transcript May 3, 2024 Fulgent Genetics, Inc. beats earnings expectations. Reported EPS is $-0.01, expectations were $-0.33. Fulgent Genetics, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Greetings, and welcome to […]